Immunology:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • HOME

      RINVOQ AD

      HUMIRA

      SKYRIZI

      SKINVERSATIONS

      SERVICES

      CONTACT

      RINVOQ (upadacitinib) logo
      RINVOQ (upadacitinib) logo
      RINVOQ (upadacitinib) logo
      INITIATION GUIDE
      PBS GUIDE
      PATIENT BOOKLET
      Key resources
      Key resources
      Clinical-Studies-download-icon-v2
      Clinical-Studies-download-icon-v2
      Find out more
      Find out more

      FIND OUT MORE ABOUT RINVOQ

      Request a call from an AbbVie Rep

      This resource is currently unavailable.
      Please contact your AbbVie Representative for further details.

      WARNING: Based on the results from a post-marketing safety study of another JAK inhibitor, RINVOQ should only be used if no suitable treatment alternatives are available in patients:
      • With history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long time smokers).
      • With malignancy risk factors (e.g. current malignancy or history of malignancy).
      • Who are 65 years of age and older.

      Refer to Product Information.

      PBS Information

      RINVOQ: Authority required. Refer to PBS Schedule for full authority information.

      Please review the full Product Information (PI) before prescribing, available below.

      RINVOQ PI

      AU-ABBV-210080. August 2023